Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis

Barua, Reeta; Templeton, Arnoud J.; Šeruga, Boštjan; Ocaña, Alberto; Amir, Eitan; Ethier, Josee-Lyne

doi:10.1016/j.clon.2018.01.003

Cited by 30 publications

(27 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the anticancer effects of MTF depend, in part, on the affected tumor site. Besides this, beneficial MTF effects have been observed in cancer-associated biomarkers and MTF has been repeatedly reported to be associated with reduced overall mortality of diabetic cancer patients, which might be, in part, attributed to beneficial MTF effects in reducing hyperglycemia and promoting weight loss and vascular protection [ 171 , 175 , 176 ]. It should be noted that MTF has enhanced anticancer effects under lower glucose levels, which can be a considerable factor in diabetic patients who are in the initial phase of MTF treatment.…”

Section: Resultsmentioning

confidence: 99%

Pleiotropic Effects of Metformin on Cancer

Schulten

2018

IJMS

View full text Add to dashboard Cite

Metformin (MTF) is a natural compound derived from the legume Galega officinalis. It is the first line antidiabetic drug for type 2 diabetes (T2D) treatment. One of its main antidiabetic effects results from the reduction of hepatic glucose release. First scientific evidence for the anticancer effects of MTF was found in animal research, published in 2001, and some years later a retrospective observational study provided evidence that linked MTF to reduced cancer risk in T2D patients. Its pleiotropic anticancer effects were studied in numerous in vitro and in vivo studies at the molecular and cellular level. Although the majority of these studies demonstrated that MTF is associated with certain anticancer properties, clinical studies and trials provided a mixed view on its beneficial anticancer effects. This review emphasizes the pleiotropic effects of MTF and recent progress made in MTF applications in basic, preclinical, and clinical cancer research.

show abstract

Section: Resultsmentioning

confidence: 99%

Pleiotropic Effects of Metformin on Cancer

Schulten

2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Clinically, Type 2 diabetes mellitus has been linked with increased risk of cancers such as those of colon/rectum, breast, bladder and pancreas, and treatment of diabetes with metformin is reported to reduce the risk of cancers . Diabetes is also a prognostic factor that influences clinical outcomes in cancer . However, a study by Häggström et al provided no support to the hypothesis that metformin protects against prostate cancer.…”

Section: Resultsmentioning

confidence: 99%

“…43,44 Diabetes is also a prognostic factor that influences clinical outcomes in cancer. [45][46][47][48] However, a study by Häggström et al 49 provided no support to the hypothesis that metformin protects against prostate cancer.…”

Section: Potential Use In Oncologymentioning

confidence: 99%

Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead

Shah

Stonier

2018

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…21 The influence of hyperglycemia on cancer survival has also been reported. In a recent meta-analysis by Barua et al, 22 hyperglycemia was shown to adversely affect OS and disease-free survival in various solid tumors, including breast, hepatocellular, pancreatic, gastric, esophageal, lung, and cervical cancer and glioblastoma. Despite the wealth of evidence demonstrating the association of hyperglycemia and cancer risk, the reported data are sparse regarding the relationship between hyperglycemia and OSCC.…”

Section: Discussionmentioning

confidence: 99%

Influence of Hyperglycemia on Treatment Outcomes of Oral Cavity Squamous Cell Carcinoma

Lien

Padua

Tay

et al. 2020

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

The present study investigated the association between perioperative hyperglycemia and the treatment and survival outcomes of patients with oral cavity squamous cell carcinoma (OSCC). Patients and Methods: From 2004 to 2016, 385 patients with OSCC were enrolled and stratified into normoglycemic (<180 mg/dL) and hyperglycemic ($180 mg/dL) groups. The clinicopathologic characteristics and treatment outcomes of OSCC were subsequently analyzed. Results: Of the 385 patients, 61 (15.8%) were in the hyperglycemic group. Hyperglycemia was significantly associated with pT stage, pN stage, overall pathologic stage, extranodal extension, albumin level, and tumor depth (P = .004, P = .042, P = .008, P = .001, P = .004, and P = .011, respectively). Patients with hyperglycemia also required a longer hospital stay (P = .003). The 5-year overall survival and diseasespecific survival were poorer in the hyperglycemic group than in the normoglycemic group (P = .001 and P = .002, respectively). Multivariate analysis revealed that hyperglycemia is a significant adverse prognostic indicator for OSCC (hazard ratio, 1.709; 95% confidence interval, 1.003 to 2.912; P = .049). Conclusions: Hyperglycemia is associated with more advanced disease and poorer survival rates in patients with OSCC. It correlates with adverse clinicopathologic characteristics and longer hospital stay. Screening for hyperglycemia and maintenance of normal glycemic status during the treatment course is imperative in the treatment of OSCC.

show abstract

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis

Cited by 30 publications

References 34 publications

Pleiotropic Effects of Metformin on Cancer

Pleiotropic Effects of Metformin on Cancer

Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead

Influence of Hyperglycemia on Treatment Outcomes of Oral Cavity Squamous Cell Carcinoma

Contact Info

Product

Resources

About